Clinical T classification predicts tumour remnants and prognosis in patients with oesophageal squamous cell carcinoma treated with neoadjuvant docetaxel/cisplatin/5-fluorouracil therapy followed by surgery

2026/07/24 by Yusuke Muneoka, Hiroshi Ichikawa, Takeo Bamba +11

paper · doi:10.1016/j.ejso.2026.112035

published in European Journal of Surgical Oncology 52(10), 112035 (Elsevier BV)

crossref created 2026/07/24 · crossref deposited 2026/08/07 · crossref indexed 2026/08/07 · crossref issued 2026/10/01 · crossref published 2026/10/01 · crossref published-print 2026/10/01

Citations

• Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
• Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial